CORRECTION: Director/PDMR Shareholding
Source: RNS09 December 2019
Kainos Group plc
("Kainos" or the "Company")
Corrected Announcement
Further to the announcement of 6 December 2019 at 15.29 under RNS number 1006W which discloses the number of Ordinary Shares held by Paul Gannon, Director, stated an incorrect number of Ordinary Shares. The correct number of Ordinary Shares held by Paul Gannon and his PCAs is 8,045,508, constituting 6.62% of the issued share capital of the Company.
The Holding(s) in Company announcement released on 6 December at 15.29 under RNS number 1009W was therefore released in error.
All other details remain unchanged. The corrected announcement is set out below.
Director / PDMR shareholdings
The Company was notified on 6 December 2019 that Paul Gannon, Director, has exercised his 2016 PSP options over 45,923 Ordinary Shares of £0.005 in the Company ("Ordinary Shares"), at an exercise price of £0.005 per Ordinary Share.
Following this notification, Paul Gannon and his PCAs have a reportable shareholding of 8,045,508 Ordinary Shares in the issued share capital of the Company, constituting 6.62% of the issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a. |
Name |
Paul Gannon |
||||
|
2. |
Reason for the notification |
|||||
|
a. |
Position/status |
Director |
||||
|
b. |
Initial notification /Amendment |
Initial |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a. |
Name |
Kainos Group plc |
||||
|
b. |
LEI |
213800H2PQMIF3OVZY47 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a. |
Description of the Financial instrument/ type of instrument Identification code |
Ordinary Shares of £0.005 each
KNOS |
||||
|
b. |
Nature of the transaction |
Exercise of Options |
||||
|
c. |
Price(s) and volume(s) |
|
||||
|
d. |
Aggregated information · Aggregated volume · Price |
N/A |
||||
|
e. |
Date of the transaction |
06-12-2019 |
||||
|
f. |
Place of the transaction |
LSE - Regulated Market - XLON |
||||
Kainos Group plc Legal Entity Identifier: 213800H2PQMIF3OVZY47
Ends
For further information, please contact:
Kainos via FTI Consulting LLP
Brendan Mooney, Chief Executive Officer
Richard McCann, Chief Financial Officer
Investec Bank plc +44 20 7597 5970
Patrick Robb / Sebastian Lawrence
Canaccord Genuity Limited +44 20 7523 4606
Simon Bridges/ Andrew Potts
FTI Consulting LLP +44 20 3727 1000
Matt Dixon / Kwaku Aning / Leah Dudley
About Kainos
Kainos Group plc is a UK-headquartered provider of Digital Services and Digital Platforms.
The Group's Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading European partner for Workday, Inc. ('Workday'), responsible for implementing Workday's innovative Software-as-a-Service (SaaS) platform for enterprise and, now, government customers.
The Group's Digital Platforms comprise specialised digital platforms in the mobile healthcare and automated testing arenas. Smart is an automated testing platform for Workday customers; Evolve Electronic Medical Records ('EMR') is the market-leading product for the digitisation of patient notes in the Acute sector of the NHS.
Kainos has over 1,550 people across 12 offices in Europe and North America.
Kainos is listed on the London Stock Exchange (LSE: KNOS). For further information, please visit www.kainos.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
